These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11706406)

  • 1. Novel agents: clinical trial design.
    Tan AR; Swain SM
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):148-53. PubMed ID: 11706406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
    Seymour L
    Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 4. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.
    Goldberg RM; Wei L; Fernandez S
    Oncologist; 2017 Sep; 22(9):1015-1019. PubMed ID: 28620092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anticancer agents.
    Weiss GR; Burris 3rd HA; Eckardt JR; Eckhardt SG; Fields SM; O'Rourke T; Rodriguez GI; Rothenberg ML; Valley AJ
    Cancer Chemother Biol Response Modif; 1996; 16():132-67. PubMed ID: 8639381
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Hidalgo M; Eckhardt SG
    J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical strategy for the development of angiogenesis inhibitors.
    Carter SK
    Oncologist; 2000; 5 Suppl 1():51-4. PubMed ID: 10804092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New phosphatidylinositol 3-kinase inhibitors for cancer.
    Bowles DW; Jimeno A
    Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-toxicity models in oncology.
    Adamina M; Joerger M
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular Targets of Active Anticancer Compounds Derived from Marine Sources.
    Song X; Xiong Y; Qi X; Tang W; Dai J; Gu Q; Li J
    Mar Drugs; 2018 May; 16(5):. PubMed ID: 29786660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring response in a post-RECIST world: from black and white to shades of grey.
    Michaelis LC; Ratain MJ
    Nat Rev Cancer; 2006 May; 6(5):409-14. PubMed ID: 16633367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
    Awada A; Mano M; Hendlisz A; Piccart M
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
    Dhani N; Siu LL
    Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.